Rapid Regression of Advanced Hepatocellular Carcinoma Associated with Elevation of Des-Gamma-Carboxy Prothrombin after Short-Term Treatment with Sorafenib – A Report of Two Cases

Publisher： Karger

E-ISSN： 1662-6575|3|2|298-303

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.3, Iss.2, 2010-08, pp. : 298-303

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 81, Iss. 3-4, 2011-11 ,pp. : 251-258

Karger

Access to resources Recommend Favorite

Complete Response after Short-Term Sorafenib Treatment in a Patient with Lymph Node Metastasis of Hepatocellular Carcinoma

By  

Case Reports in Oncology, Vol. 5, Iss. 2, 2012-07 ,pp. : 380-384

Karger

Access to resources Recommend Favorite

Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 85-92

Karger

Access to resources Recommend Favorite

Clinical significance of half‐lives of tumor markers α‐fetoprotein and des‐γ‐carboxy prothrombin after hepatectomy for hepatocellular carcinoma

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E183-E193

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 119-125

Karger

Access to resources Recommend Favorite